Rivaroxaban — CAS 755037-03-7

Rivaroxaban is an oral, direct Factor Xa inhibitor belonging to the class of novel oral anticoagulants (NOACs). It selectively and reversibly blocks Factor Xa, the pivotal enzyme in the coagulation cascade, thereby inhibiting thrombin generation and clot formation without requiring routine coagulation monitoring. Mediocon Inc manufactures GMP-compliant Rivaroxaban at its state-of-the-art facility in Aurangabad, Maharashtra, India, supplying pharmaceutical manufacturers worldwide with consistent purity and full regulatory documentation.

• Prevention of stroke and systemic embolism in non-valvular atrial fibrillation
• Treatment and secondary prevention of deep vein thrombosis (DVT)
• Treatment and prevention of pulmonary embolism (PE)
• Prophylaxis of DVT following elective hip or knee replacement surgery
• Reduction of cardiovascular events in coronary artery disease and peripheral artery disease

• GMP Certified manufacturing facility in Aurangabad, Maharashtra, India
• Full pharmacopoeial compliance: IP / BP / EP / USP standards
• Complete documentation: Certificate of Analysis (CoA), MSDS, Certificate of Origin
• Stringent in-process quality control at every manufacturing stage
• HPLC purity testing and spectroscopic identification (IR, NMR)
• Cold-chain and controlled-environment storage facilities available
• Exported to 40+ countries with full regulatory support